Clinical Trials Logo

Filter by:
NCT ID: NCT03712293 Recruiting - Clinical trials for Glioblastoma Multiforme

ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy

Start date: August 28, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2.0 used as a tool to disrupt the BBB in patients with Glioblastoma undergoing standard of care therapy.

NCT ID: NCT03710785 Recruiting - Neck Syndrome Clinical Trials

Effect of Neck Extension Exercise Using 8 Channel Surface Electromyography

Start date: October 30, 2017
Phase: N/A
Study type: Interventional

Analysis of Abnormal Muscle Activities on Forward Neck Posture Syndrome Patients and Effect of Neck Extension Exercise Using 8 Channel Surface Electromyography

NCT ID: NCT03709329 Recruiting - Clinical trials for Chronic Post-stroke Hemiplegic Patients

Effects of End-effector Type Robot Assisted Gait Therapy on Gait Pattern and Energy Consumption in Chronic Post-stroke Hemiplegic Patients

Start date: July 25, 2018
Phase: N/A
Study type: Interventional

Restoration of gait independence in stroke patients is one of the most important goals of rehabilitation therapy, and gait rehabilitation is one of the most important treatments in the treatment of stroke because it is a major factor affecting rehabilitation after stroke. In the rehabilitation of patients with post - stroke walking disorders, previous physical therapy was mainly manual therapy using therapist 's physical effort and walking training with walking aids. In recent years, however, emphasis has been placed on therapies based on motor learning concepts, which allow the patient to intensively train the exercise as closely as possible to the ultimate goal. The robot used for walking rehabilitation includes exoskeleton walking robot such as Lokomat® (Hocoma AG, Switzerland), Walkbot-G® (P & S Mechanics, Korea), MorningWalk® (Curexo, Korea) According to the Systematic Review, which compares two types of robot-assisted gait treatment divided into end-effector type, which is not an exoskeletal type such as System® (Rehatech, Switzerland) It has been reported that the percentage of patients who were able to walk independently when treated with a robot was higher than that of an exoskeleton-type robot. In this regard, in terms of acquisition of independent gait, studies on the therapeutic effect of the exoskeleton-type robot and the end-effector-type robot before and after the gait therapy were continuously performed, but 80% of the patients obtained independent gait, Despite the fact that many of these patients have abnormal walking, research has not yet been conducted. In previous studies, there was a statistically significant improvement in parameters of Gait speed, Cadence, and step length when compared with spatiotemporal parameters in training using exoskeleton robots for stroke patients. In another study, Gait speed and Cadence did not show a statistically significant improvement, and the effect on Gait speed and Cadence is still unknown. However, unlike exoskeletal robots, end-effector robotic gait training has been reported to improve Gait speed in most studies compared to conventional gait training. In addition, Cadence, Temporal symmetry ratio, Single, an improved side stride length, an improvement in the symmetry index of stance phase, and an improvement in Gait endurance. In this way, the end effector type robot walking training is more likely to improve walking quality than the exoskeleton type robot. The end-effector type robot, which is different from the exoskeleton type, reproduces the gait using the ankle joint to induce the movement of the knee joint and the hip joint. Therefore, it is possible to control the ankle joint, which is essential for improving the gait pattern. It is considered that the end effector type robot which can control the ankle joint is more likely to induce the improvement of the gait pattern than the existing exoskeleton type robot because it shows limitations in reproducing the ankle rocker motion.

NCT ID: NCT03709017 Recruiting - Clinical trials for Chronic Myeloid Leukemia

Iclusig PMS in CML or Ph+ALL Patients

Start date: October 2018
Phase:
Study type: Observational

This is a Post-Marketing Surveillance (PMS) of Iclusig® Tablets in accordance with Korean regulations on Risk Management Plan (RMP). This PMS is to assess safety and effectiveness data after administrating Ponatinib (of Iclusig® Tablets) per approved indication, usage and dosage.

NCT ID: NCT03708445 Not yet recruiting - Clinical trials for Bile Duct Obstruction, Extrahepatic

Development of a New Immunochemistry Method Using Antibodies of Proteins Related Bile Duct Cancer

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

The sensitivity of brushing cytology used to distinguish the cause of biliary strictures is low and clinical usefulness is not secured. The aim of this study was to develop a new differential staining method for cytology which is difficult to differentiate by the conventional staining method using biliary cancer related protein expressed only in bile duct cancer.

NCT ID: NCT03708016 Recruiting - Stroke Clinical Trials

Effect of Robot Gait Training With Brain Stimulation on Gait Function in Stroke Patients

Start date: October 18, 2018
Phase: N/A
Study type: Interventional

The purpose of this study was to investigate the effects of robot gait training with the noninvasive brain stimulation in stroke patients.

NCT ID: NCT03706690 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

PACIFIC-5
Start date: December 31, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable, non-small cell lung cancer (Stage III), who have not progressed following definitive, platinum-based, chemoradiation therapy.

NCT ID: NCT03706365 Not yet recruiting - Prostate Cancer Clinical Trials

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Start date: October 17, 2018
Phase: Phase 2
Study type: Interventional

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer.

NCT ID: NCT03705546 Recruiting - Lung Neoplasms Clinical Trials

The Impact of Physical Activity on the Postoperative Symptoms, Complications, and Quality of Life Among Lung Cancer Survivors

Start date: March 4, 2016
Phase:
Study type: Observational

The purpose of this study is to examine the impact of physical activity on the postoperative symptoms, complication, and quality of life.

NCT ID: NCT03704675 Enrolling by invitation - Healthy Volunteers Clinical Trials

Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects

Start date: July 25, 2018
Phase: Phase 1
Study type: Interventional

Participants in this study will receive 200 milligram (mg) TEW-7197 taken at 7days apart. One dose will be given under fasting . The Other dose will be given with a high fat meal. The study will evaluate the effect of a high fat meal on how much of the drug gets into the blood stream. Side effects will be documented. This study will last approximately 2weeks not including screening.